Despite the progress of the last few years, substantial gaps in our understanding of nucleoside resistance remain. The problem of dual resistance to zidovudine (AZT) and lamivudine (3TC) is of particular interest because viruses that are dually resistant to these two drugs show diminished susceptibility to other members of the nucleoside class. Great strides have been made in understanding the biochemical basis of resistance to the thymidine analogs, but the biochemical basis of dual resistance remains poorly understood. Similarly, the effects of novel 3TC resistance mutations such as the 44D/1181 cluster and associated polymorphisms on reverse transcriptase (RT) kinetics and viral fitness have not been studied in detail. In addition, the effects of AZT and 3TC resistance mutations on the kinetics of RT inhibition by carbovir triphosphate and PMPA diphosphate have not been studied.
Specific aims of this proposal include: 1) To study steady-state and pre-steady-state kinetics of RT from AZT/3TC-resistant biological clones of HIV-1; 2) To determine the role of pyrophosphorolysis in AZT/3TC dual resistance through primer unblocking studies performed in Collaboration with Dr. Mathias Gotte of McGill University; 3) To determine the effect of RT polymorphisms associated with dual AZT/3TC resistance on the relative fitness of dually resistant isolates; 4) To extend these studies to carbovir and PMPA; and 5) to explore the effect of other """"""""AZT-sensitizing"""""""" mutations (such as those encoding resistance to didanosine [L74V] and nevirapine [Y181C] on pyrophosphorolysis and primer unblocking. Better understanding of the virologic, genetic, and biochemical aspects of AZT/3TC dual resistance will help direct therapy and may lead to better therapeutic strategies in the future.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI042567-07
Application #
6750621
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Ussery, Michael A
Project Start
1998-01-01
Project End
2006-05-31
Budget Start
2004-06-01
Budget End
2006-05-31
Support Year
7
Fiscal Year
2004
Total Cost
$374,340
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Paredes, Roger; Sagar, Manish; Marconi, Vincent C et al. (2009) In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 83:2038-43
Paredes, Roger; Cheng, Irene; Kuritzkes, Daniel R et al. (2007) High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004. AIDS 21:2103-6
Hu, Zixin; Hatano, Hiroyu; Hammond, Sarah P et al. (2007) Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase. J Acquir Immune Defic Syndr 45:494-500
Hu, Zixin; Giguel, Francoise; Hatano, Hiroyu et al. (2006) Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 80:7020-7
Campbell, Thomas B; Shulman, Nancy S; Johnson, Steven C et al. (2005) Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 41:236-42
Lu, Jing; Whitcomb, Jeannette; Kuritzkes, Daniel R (2005) Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness. J Acquir Immune Defic Syndr 40:20-3
Miranda, Luis R; Gotte, Matthias; Liang, Fei et al. (2005) The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother 49:2648-56
Kuritzkes, Daniel R; Bassett, Roland L; Hazelwood, J Darren et al. (2004) Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr 36:600-3
Stoeckli, Thomas C; MaWhinney, Samantha; Uy, Jonathan et al. (2002) Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine. Antimicrob Agents Chemother 46:4000-3
Brown, E R; MaWhinney, S; Jones, R H et al. (2001) Improving the fit of bivariate smoothing splines when estimating longitudinal immunological and virological markers in HIV patients with individual antiretroviral treatment strategies. Stat Med 20:2489-504

Showing the most recent 10 out of 14 publications